Figures & data
Figure 1. Fecal BL NCC3001 relative abundance and associations with clinical outcomes.
![Figure 1. Fecal BL NCC3001 relative abundance and associations with clinical outcomes.](/cms/asset/aaaf441f-e0ac-4911-acb2-8d0d3e6c7086/kgmi_a_2347715_f0001_b.gif)
Figure 2. OPLS samples and variable plots.
![Figure 2. OPLS samples and variable plots.](/cms/asset/64158cde-531f-4218-afcf-19ec9c214c50/kgmi_a_2347715_f0002_b.gif)
Figure 3. Overview of changes in plasma fatty acids and bile acids.
![Figure 3. Overview of changes in plasma fatty acids and bile acids.](/cms/asset/b3334368-df75-45b0-8f09-ff60711fc981/kgmi_a_2347715_f0003_b.gif)
Figure 4. Overview of changes in plasma tryptophan, N-Acetyl tryptophan, and associations with clinical endpoints.
![Figure 4. Overview of changes in plasma tryptophan, N-Acetyl tryptophan, and associations with clinical endpoints.](/cms/asset/f011d6bc-f734-4bbd-a492-eb14eef29ec8/kgmi_a_2347715_f0004_b.gif)
Figure 5. Overview of changes in plasma butyric acid and associations with clinical endpoints and fecal BL NCC3001 counts.
![Figure 5. Overview of changes in plasma butyric acid and associations with clinical endpoints and fecal BL NCC3001 counts.](/cms/asset/952e66a5-66ef-465d-ac78-418f0a29ff53/kgmi_a_2347715_f0005_b.gif)
Table 1. Overview of plasma metabolite differences according to treatment and time.